Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers

Ki vehet részt

• Male or Female, 18 years of age or older
• Subject has a medical diagnosis of Type I or Type II Diabetes Mellitus requiring oral or glycemic control and/or insulin replacement therapy
• Subject has a diabetic foot ulcer present for 4 weeks or greater (documented in medical record) and being treated with continuous SOC
• Subject has a diabetic foot ulcer with a historical wound measurement showing less than 25% healing in 14 days prior to screening
• Subject has a diabetic foot ulcer with screening wound measurement showing less than 25% healing in 14 days prior to randomization
• Subject has a diabetic foot ulcer of Wagner grade 1 or 2
• Index ulcer is a minimum of 0.7cm2 and a maximum of 25cm2 at first treatment visit
• Diabetic foot ulcer is being treated with offloading therapy for 14 days prior to randomization
• Adequate circulation of ulcer demonstrated by an ABI of >0.7 and <1.3, or TBI of >0.6 within 30 days prior to randomization OR an arterial ultrasound noted with patent circulation and without significant stenosis 90 days prior to randomization
• Index ulcer is free of infection prior to randomization and during screening phase. Infection must be adequately treated and controlled as defined by Infectious Disease Society of America (IDSA) Guidelines PEDIS Grade 1
• Index ulcer is free of necrotic debris prior to OCMTM application
• Female subjects of childbearing potential having a negative pregnancy test prior to randomization
• Subject is able and willing to follow the protocol requirements
• Subject had signed informed consent
• If 2 or more ulcers are present, the ulcers must be separated by at least 2 cm

Ki nem vehet részt

• Concurrent participation in alternative clinical trial that involves investigational drug or device interfering with wound treatment and/or healing
• Subject with history of immunosuppressant treatment (systemic corticosteroids >10mg daily dose), cytotoxic chemotherapy, or topical steroid application to the ulcer surface for >2 weeks duration within 30 days prior to randomization; or anticipated use of the above during the course of the study
• Wound previously treated with CAMPs, tissue engineered, or scaffold materials within 14 days prior to randomization
• HBOT within 14 days prior to randomization
• Subject has major uncontrolled medical disorders in the opinion of the investigator, such as serious cardiovascular, renal, liver, pulmonary, autoimmune, palliative care, or inherited blood disorders that may affect wound healing
• Subject actively being treated for malignant disease or history of malignancy or radiation therapy at the site of wound
• Subject has comorbid conditions that may compromise subject safety in the opinion of the investigator
• Revascularization surgery on the index ulcer leg within 30 days of screening phase
• Index ulcer suspicious of neoplasm in the opinion of the principal investigator
• Subject has a known life expectance of <1 year
• Subject is unable to comply with protocol treatment
• Known contraindications to fish products or cod liver oil
• Subject is pregnant or breastfeeding
• Wound depth with visible exposed bone